What Investors Got Wrong About Neogen Before A 101% Jump

Neogen entered late 2025 with regulators ramping up food testing and analysts split on what that would mean for shareholders. For Neogen shareholders, the return over the past year was 100.5%, including dividends. If you had been weighing those bullish calls about expanding global opportunities against warnings on weak demand, integration trouble, and regulatory risk, what should that kind of outcome tell you about the business case that was on the table at the start?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Neogen has already moved. Pinpoint other ways to investigate the theme among 33 healthcare AI stocks.

What Neogen Investors Were Really Arguing About

The shares cost US$5.93 at the start of the period, and anyone looking at Neogen then had to choose between two sharply different but credible stories for where the business might be heading.

The bullish Narrative put Fair Value at US$6.5, framed around tighter food regulation and rising safety concerns supporting greater use of Neogen diagnostic tools worldwide. Supporters assumed regulatory focus, including a very large increase in federal Listeria testing on Neogen platforms, could justify higher revenue over time.

The bearish view anchored Fair Value at US$5, arguing that weaker demand and integration problems could weigh on Neogen. This camp worked off assumptions that revenue growth could decline 1.5% and that persistent operational issues from absorbing the 3M Food Safety assets might keep pressure on margins.

What The Results Changed For The Neogen Argument

Neogen’s Q1 FY 2027 update, with revenue at US$222.8 million and raised full year guidance, leaned toward the bullish case that tighter regulation and food safety demand could support higher sales. The same period delivered a loss of US$11.9 million and net margin falling from 17.4% to 5.3% below zero, so the profitability part of that optimistic story stayed unproven. Overall, the evidence cut both ways.

The hinge assumption here was not simply that Neogen could grow, but that extra testing volume would translate into healthier earnings. When you look at another diagnostics stock, track revenue, net income and margin side by side and test any growth story against whether margin and profit actually follow the top line.

What Neogen’s Recent Run Leaves You Paying For

Neogen now trades at US$11.81, with the selected Narrative placing Fair Value above that level based on tighter regulation and food safety demand. It frames recent operational changes as a margin repair story rather than just a bet on more test volume.

For anyone considering Neogen today, the Narrative argues the current price still does not fully credit a sustained shift to higher margin, more focused earnings once integration work and portfolio cleanup settle.

"Portfolio streamlining and operational improvements position Neogen for higher-margin, higher-quality earnings and sustainable competitive gains through innovation and international expansion. The company's portfolio simplification, which involves divesting lower-margin and non-core businesses (cleaners and disinfectants, genomics) and focusing on core food safety and animal health verticals, sets the stage for improved net margins and more resilient, higher-quality earnings, supported by ongoing deleveraging and reduced operational complexity."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Find Your Own Contrarian Opportunity

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

• Company 1 - 47% below our estimate - builds an aviation aftermarket platform around engine and component services and recent acquisitions.
• Company 2 - 37% below our estimate - ships lidar units at production scale for real auto deployments while already reporting profitability.
• Company 3 - 27% below our estimate - expands capacity and offerings to supply AI data center, networking and defense hardware programs.

Those are three of them. See every one of the 33 undervalued companies on it →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com